Atria Wealth Solutions Inc. Grows Position in AstraZeneca PLC (NASDAQ:AZN)

Atria Wealth Solutions Inc. raised its stake in AstraZeneca PLC (NASDAQ:AZNFree Report) by 1.4% during the 3rd quarter, reports. The firm owned 22,454 shares of the company’s stock after acquiring an additional 306 shares during the period. Atria Wealth Solutions Inc.’s holdings in AstraZeneca were worth $1,521,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Fairfield Bush & CO. acquired a new stake in shares of AstraZeneca in the second quarter valued at approximately $25,000. ICA Group Wealth Management LLC acquired a new stake in shares of AstraZeneca in the fourth quarter valued at approximately $26,000. Parkside Financial Bank & Trust boosted its holdings in shares of AstraZeneca by 4,875.0% in the first quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock valued at $26,000 after acquiring an additional 390 shares during the period. Archer Investment Corp boosted its holdings in shares of AstraZeneca by 137.0% in the second quarter. Archer Investment Corp now owns 474 shares of the company’s stock valued at $34,000 after acquiring an additional 274 shares during the period. Finally, Sunbelt Securities Inc. acquired a new stake in shares of AstraZeneca in the first quarter valued at approximately $33,000. 15.68% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Price Performance

AstraZeneca stock opened at $62.26 on Monday. AstraZeneca PLC has a one year low of $61.70 and a one year high of $76.56. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.64 and a current ratio of 0.82. The business has a fifty day moving average of $66.50 and a two-hundred day moving average of $66.69. The company has a market cap of $193.03 billion, a P/E ratio of 32.43, a price-to-earnings-growth ratio of 1.13 and a beta of 0.52.

AstraZeneca (NASDAQ:AZNGet Free Report) last released its earnings results on Thursday, February 8th. The company reported $0.73 EPS for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.01). AstraZeneca had a net margin of 13.00% and a return on equity of 30.19%. The business had revenue of $12.02 billion during the quarter, compared to analyst estimates of $12.07 billion. During the same period last year, the business posted $0.69 EPS. AstraZeneca’s revenue was up 7.3% compared to the same quarter last year. As a group, analysts predict that AstraZeneca PLC will post 4.09 earnings per share for the current fiscal year.

AstraZeneca Increases Dividend

The firm also recently announced a Semi-Annual dividend, which will be paid on Monday, March 25th. Shareholders of record on Friday, February 23rd will be issued a $0.965 dividend. The ex-dividend date is Thursday, February 22nd. This is an increase from AstraZeneca’s previous Semi-Annual dividend of $0.47. AstraZeneca’s dividend payout ratio (DPR) is 47.40%.

Analysts Set New Price Targets

Several research firms have recently weighed in on AZN. HSBC assumed coverage on AstraZeneca in a report on Monday, December 18th. They issued a “buy” rating for the company. Morgan Stanley assumed coverage on AstraZeneca in a report on Tuesday, January 23rd. They set an “overweight” rating for the company. Jefferies Financial Group downgraded AstraZeneca from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Finally, Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $80.00.

View Our Latest Research Report on AstraZeneca

About AstraZeneca

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Recommended Stories

Want to see what other hedge funds are holding AZN? Visit to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNFree Report).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.